NSCLC Phase 3 Trial of Fruquintinib Opening in China
News
The global healthcare company Hutchison China MediTech Limited (Chi-Med), has announced that its R&D subsidiary Hutchison MediPharma Limited (HMP) is beginning FALUCA, a Phase 3 registration clinical trial of fruquintinib (HMPL-013) as ... Read more